Drug Trial Radar · NCT07659782
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
105
Planned (sponsor's estimate)
Start
Jul 22, 2026
Primary completion
Jun 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- Verastem, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the safety and efficacy of VS-7375 alone in patients with metastatic KRAS G12D-mutated Non-Small Cell Lung Cancer
Conditions
- Non-Small Cell Lung Cancer
Interventions
VS-7375Drug
Taken by mouth
Primary outcomes
What the sponsor says the trial is designed to measure.
- Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1Time frame: 6 months
- To characterize the safety and tolerability of VS-7375 monotherapy administered on a daily oral schedule in participants with KRAS G12D-mutated NSCLCTime frame: 6 months
Locations
26 sites in 4 countries. Site status is shown where the registry gives one.
HonorHealth Research Institute
Scottsdale, Arizona · Recruiting
START LA
Los Angeles, California · Recruiting
Cedars-Sinai Medical Center
Los Angeles, California · Recruiting
Valkyrie Clinical Trials
Los Angeles, California · Recruiting
University of Colorado Cancer Center
Aurora, Colorado · Recruiting
BRCR Global - Coral Springs
Coral Springs, Florida · Recruiting
BRCR Global- Tamarac
Tamarac, Florida · Recruiting
Moffit Cancer Centre
Tampa, Florida · Recruiting
Emory Winship Cancer Institute
Atlanta, Georgia · Recruiting
University of Chicago
Chicago, Illinois · Recruiting
START New Jersey
East Brunswick, New Jersey · Recruiting
NYU
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina · Recruiting
START Fort Worth
Fort Worth, Texas · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
University of Utah
Salt Lake City, Utah · Recruiting
University of Virginia
Charlottesville, Virginia · Recruiting
Virginia Cancer Specialists
Fairfax, Virginia · Recruiting
Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia · Recruiting
Macquarie University Hospital
Sydney, New South Wales, Australia · Recruiting
ICON Cancer Centre South Brisbane
Brisbane, Queensland, Australia · Recruiting
Monash Health
Clayton, Victoria, Australia · Recruiting
CHU UCL Namur - Sainte-Elisabeth
Namur, Belgium · Recruiting
BRCR Global- San Juan
San Juan, Puerto Rico · Recruiting
BRCR Global- Yauco
Yauco, Puerto Rico · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.